期刊
LIFE SCIENCES
卷 91, 期 11-12, 页码 415-419出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2012.08.022
关键词
Antitumor; Breast cancer; Daidzein
资金
- Walk-for-Beauty Foundation Research Award in Breast Cancer, the School of Medicine, State University of New York at Stony Brook
Aims: This study was carried out to explore anti-breast cancer potential of isoflavone daidzein or its related compounds using appropriate animal models and their anti-tumor mechanism. Main methods: Daidzein or its major metabolite equol at a dose molar equivalent to tamoxifen [1.0 mg (2.7 mu mol)/kg or 10 mg (27 mu mol)/kg/day] was treated orally to rats bearing 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors or ovariectomized athymic nude mice implanted with human MCF-7 breast cancer xenograft and an estrogen pellet. The growth of tumors was monitored for several weeks after the treatment. The cell-cycle and apoptotic stages in mammary tumors collected from rats were analyzed by now cytometry. Immunohistochemistry analysis was also used to determine the expression of caspase-3. Key findings: Oral treatment with daidzein or equol at a human equivalent dose suppressed the growth of both DMBA-induced mammary tumors and human MCF-7 breast cancer xenografts in rodents, the inhibitory activity being superior to that of genistein or tamoxifen. Strong apoptosis induced by daidzein or equol contributes to the anti-tumor potential. Significance: Daidzein and its metabolite equol showed the potential of inhibiting the growth of mammary tumors in rodents. Daidzein or equol could be used as a core structure to design new drugs for breast cancer therapy. Our results indicate that consumption of daidzein may protect against breast cancer. (c) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据